Review: Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn's disease: Commentary

Evidence-Based Medicine

Volumn 13, Issue 4, 2008, Pages 115-

  Marshall, John K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MESALAZINE; STEROID;

CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG PREFERENCE; DRUG RESPONSE; DRUG TOLERANCE; ENTERIC FEEDING; HEALING; HIGH RISK PATIENT; HUMAN; REMISSION; SHORT SURVEY;

EID: 49749097884     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.13.4.115     Document Type: Short Survey

References (1)

1. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371: 660-7.